Naturally Occurring Mutations in HIV-1 Protease Gene Among People Living With HIV
The emergence of resistance to antiretroviral drugs is the main problem in their long-term efficacy and by considering the wide use of protease inhibitors (PIs), monitoring drug resistance mutations is necessary. Therefore, this study aimed to investigate the PIs drug resistance mutations in Iranian patients as well as subtyping using bioinformatics analysis. Fifteen Iranian patients living with Human Immunodeficiency Virus (HIV) (PLWH) were examined. RNA was used to amplify and sequence the HIV protease gene; also, HIV viral load was determined for all samples. The sequencing results were analyzed by several strong bioinformatics tools to determine the drug-resistance mutations and HIV subtypes. Some polymorphisms in the protease gene were recognized; however, there was no significant rate of major or minor drug resistance mutations in our studied patients. Subtyping analysis revealed the new subtype (D) and the previously reported ones, A and CRF-AD 35, in patients. This study confirmed that the resistance mutations and genetic polymorphisms of the protease region are rare in Iranian-infected patients that can be concluded that prescribing protease inhibitor class in HIV-infected patients is promising in controlling HIV in Iran. In addition, conducting periodic studies to determine the new mutations and the rate of drug resistance to PIs in Iranian individuals highlights the importance of WHO guidelines that recommends monitoring of genotypic-resistance testing and investigation of mutations in HIV-related genes.
2. Sanjuán R, Domingo-Calap P. Mechanisms of viral mutation. Cell Mol Life Sci 2016;73:4433-48.
3. Cartwright EK, Palesch D, Mavigner M, Paiardini M, Chahroudi A, Silvestri G. Initiation of antiretroviral therapy restores CD4+ T memory stem cell homeostasis in simian immunodeficiency virus-infected macaques. J Virol 2016;90:6699-708.
4. Ali A, Bandaranayake RM, Cai Y, King NM, Kolli M, Mittal S, et al. Molecular basis for drug resistance in HIV-1 protease. Viruses 2010;2:2509-35.
5. Lv Z, Chu Y, Wang Y. HIV protease inhibitors: a review of molecular selectivity and toxicity. HIV AIDS (Auckl) 2015;7:95-104.
6. Dehghani B, Hashempour T, Hasanshahi Z, Moayedi J. Bioinformatics Analysis of Domain 1 of HCV-Core Protein: Iran. Int J Pept Res Ther 2020;26:303-20.
7. Hashempour T, Dehghani B, Mousavi Z, Yahaghi M, Hasanshahi Z, Moayedi J, et al. Evaluating drug resistant mutations to HCV NS3 protease inhibitors in iranian Naïve patients. Int J Pept Res Ther 2019;26:1699-710.
8. Hashempour T, Dehghani B, Musavi Z, Akbari T, Hasanshahi Z, Moayedi J, et al. Association of mutations in the NS5A-PKRBD region and IFNL4 genotypes with hepatitis c interferon responsiveness and its functional and structural analysis. Curr Proteomics 2020;17:1-12.
9. Nasiri-Tajabadi Z, Najafzadeh MJ, Kalantari S, Salim FB, Garshasbi S, Jamehdar SA, et al. A Surveillance on Protease Inhibitor Resistance-Associated Mutations Among Iranian HIV-1 Patients. Arch Clin Infect Dis 2018;14:e96531.
10. Memarnejadian A, Nikpoor AR, Davoodian N, Kargar A, Mirzadeh Y, Gouklani H. HIV-1 Drug Resistance Mutations among Antiretroviral Drug-Experienced Patients in the South of Iran. Intervirology 2019;62:72-9.
11. Baesi K, Moradbeigi M, Ravanshad M, Baghban A. Phylogeny and drug resistance of HIV PR gene among HIV patients receiving RT inhibitors in Iran. Asian Pac J Trop Biomed 2016;6:451-4.
12. Davarpanah MA, Motazedian N, Joulaei H, Aghasadeghi MR, Faramarzi H, Aghah E. Comparison of antiretroviral drug resistance among treatment-naive and treated HIV-infected individuals in Shiraz, Iran. Arch Virol 2018;163:99-104.
13. Farrokhi M, Moallemi S, Shirkoohi R, Golmohammadi R, Ahsani-Nasab S, Sardashti S, et al. Antiretroviral Drug Resistance Mutations among HIV Treatment Failure Patients in Tehran, Iran. Iran J Public health 2017;46:1256-64.
14. Gholami M, Sadeghi L, Baesi K, Rouzbahani N, Mohraz M. Survey of antiretroviral drug resistance pattern among HIV-infected patients with treatment failure in Iran. J Hum Virol Retrovir 2015;3:1-6.
15. Jahanbakhsh F, Hattori J, Matsuda M, Ibe S, Monavari SH, Memarnejadian A, et al. Prevalence of transmitted HIV drug resistance in Iran between 2010 and 2011. PloS One. 2013;8:e61864.
|Issue||Vol 61 No 3 (2023)|
|Human immunodeficiency viruses (HIV) Protease Drug resistance|
|Rights and permissions|
|This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.|